A new research review published in Urologic Clinics of North America examines how treatment for non–muscle-invasive bladder cancer (NMIBC) is evolving as clinicians work to improve outcomes and address growing challenges with the long-standing standard therapy, bacillus Calmette-Guérin (BCG).
For decades, intravesical BCG has remained the gold-standard therapy for individuals with intermediate- and high-risk NMIBC because of its ability to reduce recurrence and metastasis when delivered with both induction and maintenance schedules. However, a substantial number of patients either cannot tolerate the therapy or experience disease recurrence or progression despite treatment. Global shortages of BCG have also forced clinicians to rethink dosing strategies and prioritize high-risk patients for full-dose treatment.
Learn more about bladder cancer treatment and care
The study describes a growing shift toward alternative dosing approaches and new combination strategies aimed at improving outcomes while maintaining tolerability. Dose reduction appears to preserve effectiveness in many intermediate-risk individuals, but evidence suggests reduced dosing is often insufficient for higher-risk tumors. Shorter dwell times (the time that the medication is left in the bladder before being drained) and modified schedules may help patients who struggle with side effects, though intolerance remains a significant barrier for some.
The review also emphasized the urgent need for better options for patients whose disease does not respond to BCG. Patients with early relapse or persistent high-grade disease after therapy are considered “BCG-unresponsive,” and are unlikely to see benefits from additional BCG.
Recent advances suggest new treatments may begin to fill this gap. One notable development is the approval of nogapendekin alfa inbakicept combined with BCG for adults with BCG-unresponsive NMIBC. Clinical findings showed complete response rates exceeding 60%, with a median duration of response of more than two years. Most side effects were localized, and progression to muscle-invasive disease occurred in about 10% of patients. Additional trials are investigating immune checkpoint inhibitors alongside BCG for personalized therapy.
Looking ahead, the authors point to biomarkers as a key area of future progress. Urine-based assays, cytokine panels, molecular subtyping and artificial intelligence-driven tools are under investigation to help predict which patients will benefit most from specific treatments. Although these tools are not yet ready for routine clinical use, the researchers say they could help shift care toward a more personalized, biology-driven approach to NMIBC management.
“Ultimately, the integration of biomarker-guided patient selection with rational combination and installation strategies represents the next frontier in optimizing outcomes for patients with NMIBC,” the study’s authors conclude.
Sign up here to get the latest news, perspectives, and information about bladder cancer sent directly to your inbox. Registration is free and only takes a minute.
